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Renewal of Our Value in Health Mission and Policy As We 
Enter Our Fourth Year
 
As we move into the fourth year of Value in Health’s
existence, we renew our mission to bring researchers
and decision-makers together, translating the science
of pharmacoeconomics and outcomes research into
practice.
 
VH is committed to providing papers, concepts,
and ideas that advance the fields of pharmacoeco-
nomics and outcomes research and help health
care leaders in making decisions that are solidly
evidence-based.
Health care today is faced with the multiple
challenges of:
• Limited resources;
• Ever-increasing expenditures, particularly for
drugs;
 
• Increasing expectations and greater complexity;
• Costly new technologies;
 
• And for many populations (e.g., the under-
insured, and those of lower socioeconomic sta-
tus) limited health care availability.
 
Value in Health focuses on health care worth.
Health care cost containment is not a matter of sim-
ply purchasing the cheapest drugs or other medical
inputs. Increasingly, health care leaders need pharma-
coeconomic studies, outcomes research and informa-
tion that can guide them in health care resource allo-
cation, and in evaluating alternative therapies and
interventions. We see our role as encouraging and
disseminating pharmacoeconomics and outcomes
research that will be rigorous, methodologically
solid, ethically sound, and valuable to real world
decision-makers. As the official journal of ISPOR,
our vision is to bring researchers and decision-
makers together, translating science into practice.
There is no doubt that some published cost-
effectiveness studies have biases or methodologi-
cal weaknesses that undermine their conclusions
or applicability in health care. Our goal is to set a
high scientific standard, using editorial review and
peer review not just to screen manuscripts, but to
also provide feedback for researchers in the fields
of pharmacoeconomics and outcomes research.
Sound underlying theory and attention to detail
enhances the credibility of pharmacoeconomics
and its real world applicability. We feel that some
of the theoretical foundations of pharmacoeco-
nomics and health outcomes analyses need to be
 
stronger. 
 
VH invites innovative discussion and re-
view articles on methodological topics, as well as
relevant editorials and commentary.
VH also invites research manuscripts based on
coherent models, empirical studies, and theoretical
work having pragmatic or policy-related implica-
tions.
 
 We don’t intend VH to be a predominantly
theoretical journal, but are seeking manuscripts
 
that will influence thinking and decision-making in
pharmacoeconomics, outcomes analysis, and health
 
care as a whole. 
 
VH invites editorials, policy pieces,
letters-to-the-editor, and decision-maker commentary
on VH articles
 
 to continue the dialog about how re-
searchers can better respond to the needs of those ac-
tually making clinical and financial decisions in
health care. We also welcome articles discussing spe-
cific examples of research that have had significant
impact on health care decision-making.
The combination of pharmacoeconomics and out-
comes research in a single organization and journal
creates both opportunities and difficulties, as people
with very different backgrounds and research per-
spectives interact and collaborate. Obvious comple-
mentarities across the fields exist. One cannot carry
out meaningful pharmacoeconomic research with-
out knowing the outcomes of medical interventions,
and pharmaceutical outcomes research or health pol-
icy that ignores economic reality is becoming increas-
ingly irrelevant to medical decision-making.
 
Pharmacoeconomics: Where Are We Now?
 
It sometimes seems that pharmacoeconomics is
viewed primarily as a body of techniques for eval-
uating pharmaceutical interventions in disease pro-
cesses. Processes for collection and examination of
outcomes data, health effects and costs are used by
researchers from disciplines far afield from phar-
macoeconomics and do not exclusively belong to
pharmacoeconomists; the reality is that evaluation
of pharmaceutical interventions cannot be performed
 
without these kinds of outcomes data. Therefore, 
 
VH
welcomes theoretical and empirical papers on health
effects and health costs
 
 that further the foundations
of pharmacoeconomics and improve the quality
and reliability of evaluations of pharmaceutical in-
terventions.
We also wish to further the scope of pharmaco-
economics. We define pharmacoeconomics as the
study of all behavioral, welfare and policy related
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issues affecting markets for drugs and pharmaceu-
tical services. VH hopes to attract interesting,
provocative, and worthy research not only from
pharmacoeconomists and economists, but also from
behavioral psychologists, sociologists, clinicians, eth-
icists, and others who have important things to say
about the structure, workings, and performance of
pharmaceutical and health care markets.
We hold two basic propositions as axiomatic:
1. the ultimate purpose of health care is to in-
crease the individual’s and society’s health-
related well-being; and
2. society’s health care resources ought to be allo-
cated in a way that maximizes total health-
related well being, given the size, quality, and
technological state of the resource base.
VH welcomes all original pharmacoeconomic
studies bearing on these two propositions.
More specifically, what follows is a sampling of
subjects in which we would like to see new re-
search. We use the term CEA loosely to include, in
addition to conventional cost-effectiveness analy-
ses, cost-utility analyses (based on assigning a non-
monetary metric to the valuation of outcome), cost-
consequences analyses (where the cost-effects of
interventions are elicited and compartmentalized
by decision-maker perspective), cost-minimization
analyses (where differences in outcome between in-
terventions can be legitimately disregarded) and other
comparative economic assessments. All of these tech-
niques are distinguished from cost-benefit analysis
(CBA) in which decisions to accept or reject interven-
tions are based on monetary assessments of societal
gains and losses.
 
Empirical Cost-Effectiveness Analyses (CEA)
 
Because CEA techniques are now so widely known
and used, we feel that studies published in VH
should be limited to: interventions with significant
health care impact; those of unique quality that can
serve as models of excellence for other researchers;
and those employing innovative methods applicable
as generalized techniques that will improve overall
CEA methodology.
These can be methodological or theoretical, and
may include optimization techniques, logical ratio-
nalizations of and methods for real-world decision-
making and stochastic methods.
 
Empirical Cost-Benefit Analyses (CBA)
 
The method of CBA most often used in the medical
and pharmacoeconomic literature consists of estimat-
ing the total or societal cost of an illness with and
without the proposed intervention. VH would like to
 
see new empirical cost-benefit analyses employing
the compensation (willingness-to-pay) principle stan-
dard in other economic applications of CBA, such as
public project planning and environmental policy.
 
Economic Evaluations of Private and Public Policies, 
Programs, or Practices Concerning Pharmaceutical 
Goods and Services, Including Medical Practice 
Guidelines, Private and Government Drug 
Reimbursement Policy, and Private and Government 
Regulations for Drug or Formulary Approval
 
Evaluations need not be formal CEAs or CBAs.
VH is interested in studies based on data, but will ac-
cept fact-based, logical argument as well. Traditional
empirical economic research on pharmaceutical
markets generally appears in economic journals. To
make this research and its methodology more acces-
sible to pharmacoeconomists, we hope occasionally
to publish original papers on drug pricing and mar-
keting behavior, consumer drug demand or con-
sumer drug utilization behavior, patterns of drug in-
novation and diffusion, and other facets of the
overall drug and pharmaceutical services markets.
VH also encourages studies of the economic and
health care implications of trends in these markets.
 
Outcomes Research: Where Are We Now?
 
Health care outcomes have different meanings for
different groups of people. The World Health Orga-
nization (WHO) defined health a half century ago as
a state of complete physical, mental and social well
being and not merely the absence of disease or infir-
mity. The range of relevant and valid health care
outcomes spans a broad range, from clinical mark-
ers, to hard clinical endpoints, to patient-or clinician-
reported health status and quality of life, to death.
Outcomes measurement is the systematic, valid,
and reliable assessment of objective and subjective
domains of health status that are significant to pa-
tients, their families, and those with whom they
interact. But how should outcomes be measured?
We believe that the principal benefit-related empiri-
cal outcome of any health care intervention is the
number of quality-adjusted life-years (QALYs) pro-
duced for patients, and that a QALY is superior to
any other currently used benefit-related outcome.
Moreover, if efficient allocation of health care re-
sources is society’s goal, then QALYs should be de-
fined and measured identically for all diseases, or
there will be no way to determine how closely al-
location of health care resources approaches an
optimum. Accordingly, we consider a standardized
QALY the uniquely appropriate outcome measure
of health care benefits.
 Mission and Policy Statement
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There remain many challenging empirical and
theoretical problems in the concept and measure-
ment of health-related quality of life (QoL). VH
hopes to attract interest in these problems and new,
creative efforts to solve them. In particular, 
 
VH
welcomes research that examines alternative instru-
ments or methods for measuring QoL.
 
 Because the
conclusions of empirical analyses and their policy
implications may vary with the choice of QoL in-
strument, we think it is desirable that research
adopt standardized methods for assessing QoL, and
we would like to see development of standard tests
that can be applied to QoL instruments. Some such
tests do exist. 
 
VH invites research on the develop-
ment of standard tests for QoL instruments, espe-
cially innovative ways of assessing content or con-
struct validity.
 
 We need to compare measurements
of QoL derived from different instruments for dif-
ferent populations classified by disease, symptom
severity, or other important features. Do all instru-
ments seem to capture QoL equally well over all
populations? We should compare common clinical
measures of health states with measures of QoL ob-
tained from standard instruments. VH is interested
in research analyzing clinical outcomes as predictors
of QoL. Useful predictors might be used as proxy
indicators of QoL when QoL cannot itself be di-
rectly measured. Are there other plausible ways of
assessing patient QoL? 
 
VH would like to publish
empirical studies of QoL employing hard statis-
tics, including tests and adjustments for specifica-
tion errors.
 
CEA methodology also offers opportunities for
health outcomes research. The conventional deci-
sion rule in pair-wise comparisons of interventions
states that treatment A is more cost-effective than
treatment B if the incremental cost-effectiveness
ratio defined by the two treatments is less than a
certain critical value or cutoff point. This critical
value is the highest cost of producing a QALY
over all health care interventions in current use.
Intuitively, it is the highest cost that society is cur-
rently willing to incur to produce an additional
year of quality-adjusted life. Nevertheless, no rig-
orous rationale for this crucial interpretation has
ever been offered. The fundamentals of CEA are
therefore open to the criticism that they are vague
and unsubstantiated.
In economics, the price of any commodity is de-
termined by the interacting forces of supply and
demand. Can we consider the pricing of QALYs
and the setting of societal cutoff points in a similar
manner? The direct output of the health care sys-
tem is goods and services, yet it is easy to think of
these outputs as intermediate inputs in, say, the
production of QALYs. The concepts of investment
in, the demand for, and the production of health
were proposed 25 years ago but used little since
then. Do they nevertheless contain the building ma-
terials for a demand-and-supply theory of the pricing
of QALYs? Seminal theoretical and empirical work
on the demand for years of life has appeared in the
last decade and, although its usefulness has not
been clearly established, we would like to see
more of it. If such work does prove successful, a
solid theoretical foundation for CEA is on the way.
Other benefits, such as new methods for valuing
life and estimating willingness-to-pay for life years
(as consumer surplus) would follow. We believe
that outcomes research should focus not only on
the measurement and estimation of QoL, but also
on why and how QALYs are valued by individuals
and society.
 
Cost Measurement
 
The notion of the costs of illness and treatment is
ordinarily regarded as elementary. We think such
a view is wrong. Not only are there many miscon-
ceptions about the meaning of cost, but there are
also important differences of opinion about this
meaning among competent, sophisticated research-
ers. The cost of any commodity is, of course, an op-
portunity cost—the highest market value of the
commodity in any alternative use. Opportunity cost
varies with the perspective of the cost analysis, but
it should not be confused, as it sometimes is, with
willingness to pay for well-being (as in the costing
of years of life) or to avoid the loss of well-being (as
in the costing of pain and suffering).
But more subtle difficulties than the misconstru-
ing of willingness-to-pay for costs exist. One is the
definition of the (indirect) opportunity cost of work
loss due to morbidity and premature death. The
foregone opportunity is usually defined as society’s
consumption of the individual’s labor product,
and valued as his or her discounted labor income
over the duration of lost work time. In particular,
if one accepts the assertion that the foregone op-
portunity due to morbidity or premature death is
the loss of the individuals labor product net of the
resource usage required to keep him or her alive
and well, the cost of work loss and premature
death is zero for the elderly and permanently un-
employed.
If an intervention does prolong life, how should
the resources consumed by those who would have
died without the intervention be dealt with in cost
analyses? It has been argued that the cost of this
resource use should be added to the other costs of
the intervention. Though generally ignored in em-
 4
 
Editorial
 
pirical analyses, this argument survives. If it is ac-
cepted, it is easy to think of examples, particularly
for vaccination and other disease eradication pro-
grams in impoverished countries, in which it is
much cheaper for society to let people die than to
save them. In cost-of-illness studies, the societal
cost of the illness is ordinarily characterized as a
burden. But what becomes of this burden if it is
less costly to let patients die than save them, or if
the indirect cost of sickness and death in the eld-
erly and unemployed is zero? Careful consider-
ation of the analytic perspective and the theoreti-
cal underpinnings of cost analysis are needed to
deal with these kinds of issues.
Differences of opinion regarding types of costs
that should and should not be included in CEAs
are common. One position holds that including
the (indirect) costs of lost labor due to morbidity
and premature death amounts to double counting
because the effects of the loss are already absorbed
in QALYs. All the same, the notion of opportunity
cost is unambiguous when the analytic perspective
is fixed. How therefore can it happen that a fore-
gone opportunity is given a positive value in cost-
of-illness studies and a zero value in CEAs? For
that matter, how can it be said that the highest al-
ternative market valuation of a labor product can
be represented as a number of QALYs when the
units of measurement are different?
We are not calling for a massive investigation
into the meaning of cost in pharmacoeconomics
and outcomes analysis, but the difficulties we
mention here have nontrivial consequences for ap-
plied pharmacoeconomic research and the appli-
cation of this research in public policy. Nor are
methodological difficulties unique to the specifica-
tion and estimation of costs. For this reason, we
would like VH to be an outlet for discussion and
debate about the principles and substance of phar-
macoeconomics and outcomes research. One suit-
able vehicle is the critical literature review. 
 
Re-
views of methodology, theory, and empirical findings
in special areas of health care or policy interest are
welcomed
 
. The last should incorporate author assess-
ment of the validity and implications of the research
as well as descriptions or summaries of results.
Thoughtful, state-of-the-art reviews help bring
bodies of research into clear focus.
 
Methodological Standards and Guidelines
 
Critics point out that pharmacoeconomics and out-
comes research lack consensus regarding method-
ological approaches, underlying theoretical para-
digms and presentation of results. Research in the
field is thus often viewed with skepticism regarding
bias, or the appearance of bias, in research methods,
results, and conclusions. One major goal of VH is to
serve as a forum where consensus can be built for
development of conduct and reporting guidelines.
 
We welcome articles on the philosophical founda-
tions of pharmacoeconomics and outcomes research.
 
Although these types of discussions risk being too es-
oteric for some of the journal’s anticipated audience,
if written well, they can be thought provoking and
insightful, and we feel they are an essential part of
progress in developing methodological consensus.
The value of accepted methodology standards,
even imperfect ones, far outweighs the confusion and
skepticism that exists when no standards exist. Until
a more comprehensive set of research guidelines is de-
veloped, we encourage authors where possible to uti-
lize the Reference Case methodology advocated in
the cost-effectiveness guidelines for the US Public
Health Service [1]. As researchers increasingly con-
form to standards, journal readers, research users,
and health care decision-makers will find it far easier
to apply specific findings to their own context, and to
compare results from widely differing medical inter-
ventions and therapies.
 
We also welcome letters to the editor and com-
mentary on the papers published in VH.
 
 We will
invite editorials from various sources pertaining to
the contents of issues. The only restriction placed
on editorial content in VH is that it be relevant to
the mission and objectives of VH, and it should deal
with public or private health care policy issues, inso-
far as policy is influenced by findings from pharma-
coeconomics and outcomes research.
 
Value in Health Policies On Specific Issues
 
VH has developed several policies on specific is-
sues relating to the rigorous, fair and ethical pro-
cessing and publication of submitted manuscripts;
these will be available soon on the ISPOR Value in
Health website [2]. Where no specific policy has yet
been elaborated on a specific issue, VH default pol-
icy will be that of the International Committee of
Medical Journal Editors [Uniform Requirements for
Manuscripts Submitted to Biomedical Journals [3].
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